Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 46% Improvement Relative Risk c19hcq.org Patel et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 11,468 patients in the USA Fewer cases with HCQ (p=0.0012) Patel et al., medRxiv, doi:10.1101/2022.07.13.22277606 Favors HCQ Favors control
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study
Patel et al., medRxiv, doi:10.1101/2022.07.13.22277606 (Preprint)
Patel et al., Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with.., medRxiv, doi:10.1101/2022.07.13.22277606 (Preprint)
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 11,468 vaccinated rheumatic disease patients in the USA, showing lower risk of COVID-19 with HCQ/CQ use compared with all other treatments. Adjusted results are only provided with respect to specific other treatments. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of case, 46.3% lower, RR 0.54, p = 0.001, treatment 28 of 18,358 (0.2%), control 223 of 78,509 (0.3%), cases vs. total person-months, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 15 Jul 2022, retrospective, USA, preprint, mean age 60.0, 12 authors.
Contact: zswallace@mgh.harvard.edu, jsparks@bwh.harvard.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Breakthrough infections in rheumatic disease patients Running Head: Breakthrough infections in rheumatic disease patients Title: Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study Authors: Naomi J. Patel, MD1,4; Xiaosong Wang, MS2, Xiaoqing Fu, MS1; Yumeko Kawano, MD2,4; Claire Cook, MPH1,3; Kathleen M.M. Vanni, BA2; Grace Qian, BA&Sc2; Emily Banasiak, BA2; Emily Kowalski, BS2; Yuqing Zhang, ScD1,3,4; Jeffrey A. Sparks, MD, MMSc2,4*; Zachary S. Wallace, MD, MSc1,3,4* *These authors contributed equally to this work (co-last authors). Affiliations: 1 Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA (Rheumatology Associates, 55 Fruit Street, Boston, MA, 02114) 2 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA (60 Fenwood Road, Boston, MA, 02115) 3 Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA (The Mongan Institute, 100 Cambridge Street, Suite 1600, Boston, MA, 02114) 4 Harvard Medical School, Boston, MA. Financial Support 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Breakthrough infections in rheumatic disease patients NJP is supported by the Rheumatology Research Foundation. JAS is funded by NIH/NIAMS (grant numbers, R01 AR077607, P30 AR070253, and P30 AR072577), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the Llura Gund Award for Rheumatoid Arthritis Research and Care. ZSW is funded by NIH/NIAMS [K23AR073334 and R03AR078938]. Declaration of interests NJP reports consulting fees from FVC Health unrelated to the current work. JAS reports research support from Bristol Myers Squibb and consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer. ZSW reports research support from Bristol-Myers Squibb and Principia/Sanofi and consulting fees from Zenas Biopharma, Horizon, Sanofi, Shionogi, Viela Bio, and MedPace. All other authors report no competing interests. Corresponding authors: Zachary S. Wallace, MD, MSc Clinical Epidemiology Program Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital 100 Cambridge Street, 16th Floor Boston, MA 02114 617-724-2507 zswallace@mgh.harvard.edu @zach_wallace_md 2 medRxiv preprint doi: https://doi.org/10.1101/2022.07.13.22277606; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit